144 related articles for article (PubMed ID: 35715319)
1. Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer.
Afferi L; Lonati C; Montorsi F; Briganti A; Necchi A; Mari A; Minervini A; Tellini R; Campi R; Schulz GB; Black PC; di Trapani E; de Cobelli O; Karnes RJ; Ahmed M; Mir MC; Algarra MA; Rink M; Zamboni S; Mondini F; Simeone C; Antonelli A; Tafuri A; Krajewski W; Małkiewicz B; Xylinas E; Soria F; Sanchez Salas R; Arora A; Cathelineau X; Hendricksen K; Ammiwala M; Borghesi M; Chierigo F; Teoh JY; Mattei A; Albisinni S; Roghmann F; Roumiguié M; Bajeot AS; Maier E; Aziz A; Hurle R; Contieri R; Pradere B; Carando R; Poyet C; Alvarez-Maestro M; D'Andrea D; Shariat SF; Moschini M;
Eur Urol Oncol; 2022 Dec; 5(6):722-725. PubMed ID: 35715319
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer.
Afferi L; Lonati C; Montorsi F; Briganti A; Necchi A; Mari A; Minervini A; Campi R; di Trapani E; de Cobelli O; Karnes RJ; Ahmed M; Mir MC; Algarra MA; Rink M; Zamboni S; Simeone C; Krajewski W; Xylinas E; Soria F; Hendricksen K; Einerhand S; Mattei A; Carando R; Roumiguié M; Bajeot AS; Black PC; Shariat SF; Moschini M;
World J Urol; 2022 Jun; 40(6):1489-1496. PubMed ID: 35142865
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
Pouessel D; Bastuji-Garin S; Houédé N; Vordos D; Loriot Y; Chevreau C; Sevin E; Beuzeboc P; Taille A; Le Thuaut A; Allory Y; Culine S
Clin Genitourin Cancer; 2017 Feb; 15(1):e45-e52. PubMed ID: 27554584
[TBL] [Abstract][Full Text] [Related]
5. Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection.
Morton E; Kaul S; Fleishman A; Korets R; Chang P; Wagner A; Kim SP; Bellmunt J; Kaplan I; Olumi AF; Gershman B
Urol Oncol; 2023 May; 41(5):255.e7-255.e14. PubMed ID: 36470805
[TBL] [Abstract][Full Text] [Related]
6. Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy.
Moschini M; Mattei A; Cornelius J; Shariat SF; Dell'Oglio P; Zaffuto E; Salonia A; Montorsi F; Briganti A; Colombo R; Gallina A
World J Urol; 2018 Apr; 36(4):639-644. PubMed ID: 29368231
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
[TBL] [Abstract][Full Text] [Related]
8. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
Li R; Naidu S; Fan W; Rose K; Huelster H; Grass GD; Vosoughi A; Dhillon J; Kim Y; Gupta S; Jain RK; Zhang J; Zemp L; Yu A; Poch MA; Spiess PE; Pow-Sang J; Gilbert SM; Sexton WJ
Urol Oncol; 2023 Nov; 41(11):457.e17-457.e24. PubMed ID: 37880002
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy is possibly beneficial for locally advanced or node-positive bladder cancer.
Kanatani A; Nakagawa T; Kawai T; Naito A; Sato Y; Yoshida K; Nozaki K; Nagata M; Yamada Y; Azuma T; Suzuki M; Fujimura T; Fukuhara H; Nishimatsu H; Kume H; Igawa Y; Homma Y
Clin Genitourin Cancer; 2015 Apr; 13(2):e107-12. PubMed ID: 25456839
[TBL] [Abstract][Full Text] [Related]
11. Conditional survival following radical cystectomy for urothelial carcinoma of the bladder.
Moreno MF; Kaul S; Fleishman A; Korets R; Chang P; Wagner A; Kim S; Bellmunt J; Kaplan I; Olumi AF; Gershman B
Urol Oncol; 2023 Oct; 41(10):432.e11-432.e20. PubMed ID: 37500322
[TBL] [Abstract][Full Text] [Related]
12. The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration.
Afferi L; Zamboni S; Karnes RJ; Roghmann F; Sargos P; Montorsi F; Briganti A; Gallina A; Mattei A; Schulz GB; Hendricksen K; Voskuilen CS; Rink M; Poyet C; De Cobelli O; di Trapani E; Simeone C; Soligo M; Simone G; Tuderti G; Alvarez-Maestro M; Martínez-Piñeiro L; Aziz A; Shariat SF; Abufaraj M; Xylinas E; Moschini M;
World J Urol; 2021 Feb; 39(2):443-451. PubMed ID: 32356226
[TBL] [Abstract][Full Text] [Related]
13. Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: Clinical outcomes and development of a postoperative risk stratification model.
Al-Alao O; Mueller-Leonhard C; Kim SP; Amin A; Tucci C; Kott O; Mega A; Golijanin D; Gershman B
Urol Oncol; 2020 Mar; 38(3):76.e19-76.e28. PubMed ID: 31590968
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
Shimizu F; Muto S; Taguri M; Ieda T; Tsujimura A; Sakamoto Y; Fujita K; Okegawa T; Yamaguchi R; Horie S
Int J Urol; 2017 May; 24(5):367-372. PubMed ID: 28281310
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients.
Lucca I; Rouprêt M; Kluth L; Rink M; Tilki D; Fajkovic H; Kassouf W; Hofbauer SL; de Martino M; Karakiewicz PI; Briganti A; Trinh QD; Seitz C; Fritsche HM; Burger M; Lotan Y; Kramer G; Shariat SF; Klatte T
BJU Int; 2015 May; 115(5):722-7. PubMed ID: 24905084
[TBL] [Abstract][Full Text] [Related]
16. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
18. Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy.
Moschini M; Morlacco A; Briganti A; Hu B; Colombo R; Montorsi F; Frank I; Daneshmand S; Karnes RJ
Eur Urol Focus; 2018 Mar; 4(2):245-251. PubMed ID: 28753820
[TBL] [Abstract][Full Text] [Related]
19. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.
Zargar-Shoshtari K; Zargar H; Dinney CP; Ercole CE; Sharma P; Kovac E; Grivas PD; Stephenson AJ; Shah JB; Black PC; Spiess PE
World J Urol; 2016 May; 34(5):695-701. PubMed ID: 26286880
[TBL] [Abstract][Full Text] [Related]
20. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
